Dr Reddy’s numbers on expected lines, outlook on company remains positive: Analysts

Dr Reddy’s Laboratories (DRL) today reported a good set of numbers for Q2FY21.

“DRL numbers are on the expected line,” said Cyndrella Carvalho of Centrum Broking in an interview with CNBC-TV18. The outlook on the company remains positive, she added.

Vishal Manchanda, Pharma Analyst of Nirmal Bang Institutional Equities, said, “Numbers continue to outperform. Even this quarter was a beat on the consensus numbers largely driven by India doing extremely well.”

“We remain in momentum and this momentum should continue to build with every quarter as they launch some big products in the US, very good set of numbers,” Manchanda added.